ARTICLE | Company News
Intradigm, Sequitur deal
June 16, 2003 7:00 AM UTC
The companies partnered to research and develop RNAi-based therapeutics. Under the deal, the companies will cross-license respective related technologies, including Sequitur's Stealth modified RNAi te...